Paris (France) and Cambridge (Massachusetts, U.S.), June 2, 2026, at 7:00 a.m. CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a pioneer in the development of transformative therapies targeting longevity, today announced the submission of the registration filing for its joint venture in Hong Kong with its Asian partners, including Ronghui Renhe Life Technology, a leading Chinese conglomerate primarily engaged in the manufacturing and distribution of healthcare products.
Biophytis strengthens its financial position and extends its cash runway into Q1 2027
Cash position strengthened to €3.0 million Most 2026 share warrants exercised Phase 2 study in obesity to start in Q1 2027 Hong-Kong JV to start operations for preparing Phase 3…
